Omar Marques | Lightrocket | Getty Images
UnitedHealth Group Chairman and CEO Stephen Hemsley will face the first real test Tuesday of his ability to regain investor confidence as the largest private U.S. insurer reports earnings.
The Dow component has seen its share price cut nearly in half since mid-May, with the stock on pace for its worst year in more than a decade, after earnings in its flagship Medicare program and Optum Health physician practices plummeted. That led to the abrupt resignation of former CEO Andrew Witty, forcing the company to reinstate ex-CEO Hemsley to replace him and suspend earnings guidance. On top of that, the company is facing criminal and civil Department of Justice investigations into its Medicare billing practices.
As UnitedHealth faces challenges on multiple fronts, it sits in a “perfect storm,” said Mizuho Securities analyst Ann Hynes. Now, investors want to know how Hemsley plans to steer the company out of the whirlwind, after assuring them last June that “we’re humbly determined to earn back your trust and your confidence.”
Here are three key things investors will be looking for from the company’s earnings report.
The big number: 2025 guidance
More so than the second-quarter numbers, analysts are focused on UnitedHealth’s outlook for the full year. Hemsley told investors the company would provide an update on 2025 earnings guidance, after it suspended its forecast in May.
Analysts expect UnitedHealth to post adjusted full-year earnings of $21.26 per share, according to consensus estimates from LSEG. Estimates range from a low of $18 per share to a peak of $26.44 a share.
“Anything below $18 — that would be viewed as a negative by the street,” Hynes said
RBC Capital Markets analyst Ben Hendrix has set his estimate above consensus at $23.36, but said Wall Street remains bearish on UnitedHealth.
“While we base our more optimistic outlook on management’s assertion that Medicare Advantage remains profitable with the 3% low-end of target MA margin in sight for 2026, clients we’ve spoken to have expressed concern over continued margin compression in OptumHealth and accelerating (medical cost) trend in core Medicare Advantage,” he wrote in a note earlier this month.
Medicare Advantage and Optum Health outlook
Analysts are also focused on how the company plans to stabilize its physician practice unit, Optum Health. For years, it helped UnitedHealth outperform its peers in its flagship Medicare Advantage program, by leveraging its 90,000 employed or affiliated doctors to treat patients on UnitedHealth’s own plans.
“Investors with duration were investing in United really for the power of … Optum Health, the power of United steering their own Medicare Advantage members, extracting considerable margin that they hadn’t been able to before,” said Baird analyst Michael Ha.
But in the first quarter this year, Optum Health saw a sharp decline in profits. Analysts said the plunge was due in part to a Biden-era change in Medicare reimbursement standards known as V28, which is making it harder for insurers and doctors to bill for extra services.
Mizuho’s Hynes said prior billing coding rules left a lot more room for plans to add billing codes related to chronic conditions, such as overall heart conditions, which would provide a higher risk score and reimbursement rate. Under the new V28 rule the billing codes are more specific, closing loopholes that could boost reimbursement.
“V28 is very black and white, so you don’t have that kind of ability to add codes, and a lot of codes are removed,” she said, adding that has now “led to a structural shift in margins for Optum Health.”
But Ha noted the V28 changes began in 2024, at a time when seniors started utilizing more care. Many of UnitedHealth’s Medicare Advantage competitors made adjustments over the last year to address the shift. The sudden collapse of Optum Health margins in the first quarter appears to have caught UnitedHealth off guard.
“I think it’s an example of misexecution. They knew the headwind heading into the year and even well before then, but for one reason or another couldn’t find the offset,” Ha said. “We’re still confident that Optum Health and United can recover and rebuild unit economics, but we think over the next one to two years, it may potentially worsen.”
Legal and regulatory issues
The company got out ahead of the earnings report on Thursday, acknowledging in an SEC filing that its Medicare program billing practices face criminal and civil probes by the Department of Justice.
UnitedHealth said the company is cooperating the with the investigations, first reported by the Wall Street Journal. It also noted that in March, a court-appointed special master ruled in the company’s favor in a case involving similar allegations brought by the DOJ during the first Trump administration.
Hynes believes investor concern over the DOJ probes has been overblown.
“The stock is trading like the government’s going to kick them out of Medicare and Medicaid, and the likelihood of that is zero, in my view,” she said. “It will probably end up with them writing a check and doing a Corporate Integrity Agreement … that’s what has happened in the past.”
But the shooting death of UnitedHealth executive Brian Thompson last December, which prosecutors allege was carried out by a gunman who was motived by insurance denials, unleashed a groundswell of public criticism of health insurers’ practices.
Former whistleblower Wendell Potter, who has criticized industry practices after a career at Cigna, said the pressure on large insurers like UnitedHealth likely will not cease. Regulatory scrutiny in Congress has increased on both sides of the aisle, as Washington grapples with high health and drug costs in Medicare, Medicaid and other government health programs.
“A lot of the members of Congress who are doctors or Republicans, some are pharmacists, and they see firsthand the heavy hand of these companies,” said Potter, president of the Center for Health and Democracy. “And so you’re seeing interest by Republicans, and I’ve not seen that before.”
In June, UnitedHealth announced that it had hired third party auditors to conduct a review of the company’s practices in health insurance and pharmacy benefits services, in an effort “to provide our stakeholders transparency and confidence” in the company’s business practices.
The company told CNBC it will not have many details to offer about that audit during the second-quarter earnings call. It does not expect the review to be completed until the end of the third quarter of this year.
![Mercedes gives first look at the GLB EV interior and it’s loaded with massive screens [Images]](https://i0.wp.com/electrek.co/wp-content/uploads/sites/3/2025/11/Mercedes-GLB-EV-first-look.jpeg?resize=1200%2C628&quality=82&strip=all&ssl=1 "Mercedes gives first look at the GLB EV interior and it’s loaded with massive screens [Images]")
![From $189 a month: 5 of the best EV lease deals in November [Updated]](https://i0.wp.com/electrek.co/wp-content/uploads/sites/3/2025/07/Hyundai-new-IONIQ-6-EV-8.jpeg?resize=1200%2C628&quality=82&strip=all&ssl=1 "From $189 a month: 5 of the best EV lease deals in November [Updated]")
